Back

Perspective Therapeutics announces Merck collaboration to evaluate [212Pb]PSV359 with Keytruda

Verifying
  • Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck.
  • The agreement covers [212Pb]PSV359 combined with Keytruda (pembrolizumab).
  • The combination will be evaluated in FAP-α-positive solid tumors.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.